Nama's AI scorecard currently rates Calumet Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is CLMT's P/E ratio?

Calumet trades at a trailing price-to-earnings ratio of 136.7.

When does CLMT report earnings?

Calumet's next scheduled report is on Feb 26, 2027. Analysts expect EPS of $1.07.

What is the CLMT price target?

The median analyst price target from 5 analysts is $57.00, with a range of $40.00 – $75.00.

Is CLMT Shariah compliant?

Nama's AAOIFI-style screen reads Calumet as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Calumet (CLMT)

Basic Materials · Specialty Chemicals · NASDAQ

Calumet (CLMT) is a Basic Materials company in the Specialty Chemicals industry. It has a market capitalization of $3.48B, a trailing price-to-earnings ratio of 136.7 and a free-cash-flow yield of 1.6%. Over the most recent reported fiscal year, revenue declined 1.2%. Nama's AI scorecard rates it Sell, 2.5 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 2.5/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Leading · +188.5% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-33.8%

How far the last close sits under the highest price of the past five years.

Market cap	$3.48B
Trailing P/E	136.7
Price / book	—
Price / sales	0.8
FCF yield	1.6%
Dividend yield	—
Gross margin	6.6%
Operating margin	1.2%
Net margin	-3.0%
Revenue growth (YoY)	-1.2%
Revenue growth (3-yr annual)	-4.1%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.8
Exchange	NASDAQ
Sector	Basic Materials
Industry	Specialty Chemicals

CLMT earnings

Next report: Feb 26, 2027 (Q4 2026, EPS estimate $1.07). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 6, 2026	$2.79	$1.80	+55.0%	—
Q2 2026	Aug 7, 2026	$0.68	$0.16	+325.0%	$1.45B
Q1 2026	May 8, 2026	-$0.41	-$0.63	+34.9%	$1.03B
Q4 2025	Feb 27, 2026	-$0.18	-$0.45	+60.0%	$1.04B

CLMT analyst price target

Median target $57.00 from 5 analysts, ranging $40.00 – $75.00.

Specialty Chemicals peers

Ticker	Company	Market cap	P/E
LIN	Linde	$236.54B	30.9
ECL	Ecolab	$84.33B	37.4
SHW	Sherwin-Williams	$83.13B	28.9
APD	Air Products and Chemicals	$67.88B	22.7
PPG	PPG Industries	$27.03B	15.7
IFF	International Flavors & Fragrances	$20.69B	22.3
LYB	LyondellBasell Industries	$19.63B	8.6
DD	DuPont de Nemours	$19.42B	20.9

Explore live CLMT data on Nama Insights →

CLMT FAQ

Is CLMT a buy?: Nama's AI scorecard currently rates Calumet Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is CLMT's P/E ratio?: Calumet trades at a trailing price-to-earnings ratio of 136.7.
When does CLMT report earnings?: Calumet's next scheduled report is on Feb 26, 2027. Analysts expect EPS of $1.07.
What is the CLMT price target?: The median analyst price target from 5 analysts is $57.00, with a range of $40.00 – $75.00.
Is CLMT Shariah compliant?: Nama's AAOIFI-style screen reads Calumet as Not Shariah Compliant. At least one of the three ratios or the industry test failed.